Alector, Inc. - Common Stock (ALEC)
1.8400
0.00 (0.00%)
Alector Inc is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases by harnessing the immune system
The company aims to discover and bring to market treatments that address the underlying mechanisms of conditions such as Alzheimer's disease. Through advanced research and a proprietary platform, Alector is dedicated to unlocking new pathways in neuroscience and providing hope for patients dealing with these challenging diseases. Their strategic approach combines drug development with a strong emphasis on understanding the interactions between the immune system and the nervous system.
![](https://cdn.benzinga.com/files/images/story/2024/12/04/Brain-Degenerative-Diseases-Parkinson--A.jpeg?width=1200&height=800&fit=crop)
Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.
Via Benzinga · December 4, 2024
![](https://talkmarkets.com/images/logos/talkmarkets.png)
Via Talk Markets · November 30, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 26, 2024
![](https://cdn.benzinga.com/files/images/story/2024/11/26/opec-oil-shutter.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 26, 2024
![](https://cdn.benzinga.com/files/images/story/2024/11/26/Philadelphia--Pennsylvania--May-19-2018-_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 26, 2024
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image.jpeg?width=1200&height=800&fit=crop)
Companies Reporting Before The Bell • Gaotu Techedu (NYSEGOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via Benzinga · February 27, 2024
![](https://cdn.benzinga.com/files/images/story/2024/eye-5248678.jpeg?width=1200&height=800&fit=crop)
Alector shares are trading lower by 14.9% during Wednesday's session. The company announced the pricing of a $75 million public offering.
Via Benzinga · January 17, 2024
![](https://cdn.benzinga.com/files/images/story/2024/11/26/Understanding-Alzheimers.jpeg?width=1200&height=800&fit=crop)
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%.
Via Benzinga · November 26, 2024
![](https://cdn.benzinga.com/files/images/story/2024/11/26/movers-image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 26, 2024
![](https://cdn.benzinga.com/files/images/story/2024/11/26/movers-image.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 26, 2024
![](https://cdn.benzinga.com/files/images/story/2024/06/10/xrdDAFn2TQBVk42-j1686993718079065616-t23.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · June 10, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
ALEC stock results show that Alector beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 8, 2024
![](https://www.investors.com/wp-content/uploads/2024/03/TECHpic-brain-040124-shutt.jpg)
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Via Investor's Business Daily · March 28, 2024
![](https://investorplace.com/wp-content/uploads/2021/04/wall-street-federal-hall.jpg)
We're starting Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on this morning!
Via InvestorPlace · March 6, 2024
![](https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600.png)
These three companies are developing treatments for brain diseases that have a great deal of potential, making them top neuroscience stocks.
Via InvestorPlace · January 23, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/17/image24.jpeg?width=1200&height=800&fit=crop)
Shares of Airspan Networks Holdings Inc. (NASDAQMIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module. Airspan Networks Holdings shares surged 381% to $0.3699 on Wednesday.
Via Benzinga · January 17, 2024
![](https://cdn.benzinga.com/files/images/story/2024/01/17/image46.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded lower, with the Nasdaq Composite falling more than 150 points on Wednesday.
Via Benzinga · January 17, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 16, 2024
![](https://www.investors.com/wp-content/uploads/2024/01/A1-010824-biotech-Gash.jpg)
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via Investor's Business Daily · January 5, 2024
![](https://cdn.benzinga.com/files/images/story/2023/12/15/image48.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Friday. Here are some other big stocks recording gains in today’s session.
Via Benzinga · December 15, 2023
![](https://cdn.benzinga.com/files/images/story/2023/12/14/alec.png?width=1200&height=800&fit=crop)
Stifel has upgraded Alector Inc (NASDAQALEC), noting that while Alzheimer's is a very high risk, the probability of success for AL002 (TREM2 agonist) is above average, and the stock risk/reward is highly attractive ahead of phase 2 data in expected in Q4 2024.
Via Benzinga · December 14, 2023
![](https://cdn.benzinga.com/files/images/story/2023/12/14/image30_0.jpeg?width=1200&height=800&fit=crop)
Shares of Amtech Systems, Inc. (NASDAQASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales guidance below estimates.
Via Benzinga · December 14, 2023